“Non-Interference” And Part D: Prescriber Oversight Is Focus Of CMS Final Rule
This article was originally published in RPM Report
Executive Summary
CMS’ final rule on Part D is much narrower than the agency’s proposed rule—and most in industry are probably pleased by that. But it is also much more one-sided, emphasizing new tools to monitor for and correct “abusive” prescribing, without any countervailing provisions reflecting the value of appropriate medication adherence.